Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)
Original languageEnglish
Pages (from-to)381-382
Number of pages2
JournalPharmacoeconomics (Print)
Volume36
Issue number3
DOIs
Publication statusPublished - 2018

Cite this